GAVISCON Tablets Chewable 500/25/100 Milligram

Country: আয়ার্লণ্ড

ভাষা: ইংরেজি

সূত্র: HPRA (Health Products Regulatory Authority)

সক্রিয় উপাদান:

ALGINIC ACID MAGNESIUM TRISILICATE ALUMINIUM HYDROXIDE GEL, DRIED SODIUM BICARBONATE

থেকে পাওয়া:

Reckitt Benckiser Ireland Ltd

ডোজ:

500/25/100 Milligram

ফার্মাসিউটিকাল ফর্ম:

Tablets Chewable

অনুমোদন তারিখ:

1998-04-01

পণ্য বৈশিষ্ট্য

PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Gaviscon Tablets 
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 500mg Alginic acid, 170 mg
sodium bicarbonate, 100 mg Aluminium Hydroxide Gel and 25mg 
Magnesium Trisilicate.
For excipients, see 6.1
3 PHARMACEUTICAL FORM
Chewable tablet.
Circular, flat, off-white to cream, bevel-edged tablets, 0.9
inches in diameter with an odour and flavour of peppermint, 
with ‘Gaviscon’ and sword motif imprinted on both faces.
4 CLINICAL PARTICULARS 
4.1 THERAPEUTIC INDICATIONS
Gastric reflux, reflux oesophagitis, heartburn, hiatus hernia,
heartburn (including heartburn of pregnancy) and similar 
gastric distress.
4.2 POSOLOGY AND METHOD OF ADMINSTRATION
Oral.
Adults and children over 12
years: One or two tablets after meals and at bedtime.
Children 6 to 12 years: One tablet after meals and at bedtime.
4.3 CONTRAINDICATIONS
None known.
4.4 SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
Sodium content of a tablet is 47 mg (2.04 mmol). This should
be taken into account when a highly restricted salt diet is 
required as in some renal and
cardiovascular conditions. Products containing
aluminium hydroxide should be used 
with caution in patients with renal dysfunction
or hypophosphataemia.
Aluminium hydroxide may cause constipation due to
its astringent action; this effect may be balanced by
the cathartic 
effect of the magnesium salts.
Aluminium hydroxide may lead to a phosphate depletion syndrome,
particularly in patients on a low phosphate diet, 
e.g. malnutrition.
Magnesium salts may cause central nervous depression in
the presence of renal insufficiency and should not be used in 
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Issued 22/09/2005_
_CRN 2014934_
_page number: 1_
patients